DermatologyNews.net

Dermatology Xagena

XagenaNewsletter
Xagena Mappa
Medical Meeting
Pneumobase.it

Search results for "Plaque psoriasis"

FDA ( Food and Drug Administration ) approved an expanded indication for Enbrel ( Etanercept ) to improve physical function in patients with psoriatic arthritis. In addition, the FDA approved an up ...


Raptiva ( Efalizumab) is indicated for the treatment of adult patients ( 18 years or older ) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ...


The European Commission has granted approval of Remicade ( Infliximab ), an anti-tumor necrosis factor alpha ( TNF-alpha ) blocker, for the treatment of moderate to severe plaque psoriasis. The new ...


Two clinical trials of Humira ( Adalimumab ), REVEAL and CHAMPION, have demonstrated promising results in psoriasis. Psoriasis is a chronic autoimmune disease that speeds the growth cycle of skin ...


A study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of Ustekinumab ( Stelara ) achieved at least a 75 percent reduction in psoriasis at we ...


Raptiva ( Efalizumab ) is an immunosuppressive, humanized monoclonal antibody indicated for treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to ...


The statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase III studies. ESTEEM 1 ...


Phase II data, published in the New England Journal of Medicine ( NEJM ), have showen that Ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe p ...


The results from the head-to-head phase III FIXTURE study showing Secukinumab ( AIN457 ), an interleukin-17A ( IL-17A ) inhibitor, was significantly superior to Etanercept ( Enbrel ) in moderate-to-se ...


Tofacitinib ( Xeljanz ) is a novel, oral Janus kinase inhibitor currently under investigation for plaque psoriasis. This exploratory analysis of a phase IIb, 12-week, dose-ranging study has evaluat ...


New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis were presen ...


A man with almost no hair on his body has grown a full head of it after a novel treatment by clinicians at Yale University. There is currently no cure or long-term treatment for alopecia universalis, ...


A meta-analysis has evaluated the efficacy and safety of Ustekinumab ( Stelara ) in the therapy of plaque psoriasis. The efficacy was estimated using relative risk of Psoriasis Area and Severity In ...


The Dermatologic and Ophthalmic Drugs Advisory Committee ( DODAC ) to the US Food and Drug Administration ( FDA ) has voted unanimously to support the approval of AIN457 ( Secukinumab ), a selective i ...


Results from two pivotal phase III studies evaluating the interleukin-17A ( IL-17A ) inhibitor Secukinumab ( AIN457 ) were published in the New England Journal of Medicine ( NEJM ). Secukinumab met ...